Mouse Genome Informatics
cn
    Mybl2tm1.1Jof/Mybl2+
Tg(Zp3-cre)3Mrt/0

involves: 129S2/SvPas * C57BL/6 * FVB/N
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
hematopoietic system
• peripheral blood of mice that develop MDS shows dyserythropoiesis that includes anisocytosis and poikilocytosis and the presence of Howell-Jolly bodies
• decrease in red blood cells in mice that develop MDS or MPN
• in mice that develop MDS
• signs of anemia and changes in white blood cell counts are detectable between 12 and 18 months of age and exacerbated by 22 months
• in mice that develop MDS
• in mice that develop MDS
• decrease in white blood cells in mice that develop MDS
• peripheral blood of mice that develop MDS shows neutropenia
• increase in white blood cells in mice that develop MPN
• the mouse that develops myeloid leukemia shows a dramatic increase in the percentage of granulocytes
• the mouse that develops myeloid leukemia shows a dramatic increase in the percentage of monocytes
• some mice show thrombocytopenia and others thrombocytosis
• some mice show thrombocytopenia and others thrombocytosis
• 12 of 13 mice at 22 months of age show multiple myeloid disorders
• 46% (6 of 13) of mice develop myelodysplasia (MDS)
• 38% (5 of 13) of mice develop myeloproliferative neoplasms (MPN)
• 7% (1 of 13) of mice develop myeloid leukemia
• transplantation of mutant bone marrow cells into lethally irradiated recipients accelerates development of MDS
• peripheral blood and spleen of mice that develop MDS show an increase in myeloid populations
• 3 of 5 mice that develop MPN, with or without anemia, with or without thrombocytopenia, show an increase in the myeloid population in peripheral blood, bone marrow, and spleen
• mutants that develop MPN show myeloproliferation in the bone marrow with high cellularity and practically no fat cells
• 9 of 13 mice have enlarged spleens at 22 months of age

immune system
• decrease in white blood cells in mice that develop MDS
• peripheral blood of mice that develop MDS shows neutropenia
• increase in white blood cells in mice that develop MPN
• the mouse that develops myeloid leukemia shows a dramatic increase in the percentage of granulocytes
• the mouse that develops myeloid leukemia shows a dramatic increase in the percentage of monocytes
• 12 of 13 mice at 22 months of age show multiple myeloid disorders
• 46% (6 of 13) of mice develop myelodysplasia (MDS)
• 38% (5 of 13) of mice develop myeloproliferative neoplasms (MPN)
• 7% (1 of 13) of mice develop myeloid leukemia
• transplantation of mutant bone marrow cells into lethally irradiated recipients accelerates development of MDS
• peripheral blood and spleen of mice that develop MDS show an increase in myeloid populations
• 3 of 5 mice that develop MPN, with or without anemia, with or without thrombocytopenia, show an increase in the myeloid population in peripheral blood, bone marrow, and spleen
• 9 of 13 mice have enlarged spleens at 22 months of age

tumorigenesis
• 7% (1 of 13) of mice develop myeloid leukemia with marked leukocytosis, anemia, and in increase in the number of platelets
• the one mouse that develops a myeloid neoplasm shows the mild increase in platelet number and anemia at 12 to 18 months of age, whereas the massive increase of white blood cells starts after 18 months of age
• the mouse that develops a myeloid neoplasm shows immature myeloid cells in the blood, exhibits white bones, splenomegaly, and disruption of spleen architecture with loss of lymphatic follicles and an increase in the number of megakaryocytes and infiltration of myeloid cells in the liver

Mouse Models of Human Disease
OMIM IDRef(s)
Leukemia, Acute Myeloid; AML 601626 J:196804
Myelodysplastic Syndrome; MDS 614286 J:196804